Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the Price/FCF ratio high or low?
The Price/FCF ratio of 39.19 is 66% below its estimated 1-year average of 116.25, near the low end of its estimated 1-year range (39.19–130.20).
As of 2026-10-06T15:42:35.507Z.
Calculation as of: 2026-10-06T15:42:35.507Z.
Quote observation: 2026-10-06T15:40:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 295890ca45b9fb7c845dc9b7cfc12ce3e82df22f7cd737cbd4420fef5fb5231a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
39.19
PRICE/FCF RATIO AVG TTM
N/A
PRICE/FCF RATIO AVG 3Y
N/A
PRICE/FCF RATIO AVG 5Y
N/A
PRICE/FCF RATIO AVG 10Y
N/A
PRICE/FCF RATIO AVG 15Y
N/A
PRICE/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
21.27
median of 181 covered companies
CURRENT VS SECTOR MEDIAN
+84.25%
vs the sector median at left
Market Cap
$2.38B
Price/FCF Ratio
N/A
TTM Avg
126.91
3Y Avg
126.91
5Y Avg
126.91
Market Cap
$2.38B
Price/FCF Ratio
20.48
TTM Avg
65.29
3Y Avg
92.84
5Y Avg
92.84
Market Cap
$2.41B
Price/FCF Ratio
32.44
TTM Avg
38.73
3Y Avg
40.68
5Y Avg
38.72
Market Cap
$2.32B
Price/FCF Ratio
6.54
TTM Avg
6.22
3Y Avg
8.21
5Y Avg
14.22
Market Cap
$2.44B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.29B
Price/FCF Ratio
N/A
TTM Avg
6.98
3Y Avg
9.73
5Y Avg
13.98
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Liquidia Corporation (LQDA) | $2.37B | 39.19 | N/A | N/A | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.38B | N/A | 126.91 | 126.91 | 126.91 |
| ADMA Biologics, Inc. (ADMA)vs › | $2.38B | 20.48 | 65.29 | 92.84 | 92.84 |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | 32.44 | 38.73 | 40.68 | 38.72 |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.41B | N/A | N/A | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.32B | 6.54 | 6.22 | 8.21 | 14.22 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.44B | N/A | N/A | N/A | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.29B | N/A | 6.98 | 9.73 | 13.98 |
| Disc Medicine, Inc. (IRON)vs › | $2.46B | N/A | N/A | N/A | N/A |
| Pharvaris N.V. (PHVS)vs › | $2.16B | N/A | N/A | N/A | N/A |
P/FCF Ratio
39.2
FCF Yield
2.55%
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/FCF RATIO |
|---|---|
| 2026-10-05 | 46.32 |
| 2026-10-02 | 47.99 |
| 2026-10-01 | 46.90 |
| 2026-09-30 | 50.71 |
| 2026-09-29 | 118.45 |
| 2026-09-28 | 123.45 |
| 2026-09-25 | 114.66 |
| 2026-09-24 | 118.89 |
| 2026-09-23 | 113.09 |
| 2026-09-22 | 115.02 |
| 2026-09-21 | 111.31 |
| 2026-09-18 | 112.07 |
| 2026-09-17 | 114.60 |
| 2026-09-16 | 114.70 |
| 2026-09-15 | 110.12 |
| 2026-09-14 | 109.44 |
| 2026-09-11 | 111.83 |
| 2026-09-10 | 113.69 |
| 2026-09-09 | 115.82 |
| 2026-09-08 | 113.41 |
| 2026-09-04 | 115.05 |
| 2026-09-03 | 115.00 |
| 2026-09-02 | 116.76 |
| 2026-09-01 | 112.12 |
| 2026-08-31 | 114.23 |
| 2026-08-28 | 113.42 |
| 2026-08-27 | 117.20 |
| 2026-08-26 | 119.57 |
| 2026-08-25 | 118.12 |
| 2026-08-24 | 117.75 |
| 2026-08-21 | 114.98 |
| 2026-08-20 | 119.06 |
| 2026-08-19 | 126.23 |
| 2026-08-18 | 124.55 |
| 2026-08-17 | 130.20 |
| 2026-08-14 | 124.74 |
| 2026-08-13 | 120.81 |
